Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hematologic Neoplasms × acalabrutinib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 27 Lymphoma, Mantle-Cell 12 Lymphoma, Non-Hodgkin 6 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma 4 Leukemia, B-Cell 3 Waldenstrom Macroglobulinemia 2 Recurrence 2 Multiple Myeloma 2 Lymphoma, Follicular 2 Lymphoma, B-Cell 2 Leukemia, Prolymphocytic 2 Leukemia 2 Squamous Cell Carcinoma of Head and Neck 1 Part1: Advanced B-cell Malignancies 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphatic Diseases 1 Leukemia, Hairy Cell 1 Immunoproliferative Disorders 1 Immune System Diseases 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Heart Failure 1 Glioblastoma 1 DLBCL 1 Chromosome 17 deletion 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Azacitidine 11 venetoclax 7 AP 1903 reagent 6 Itraconazole 5 fludarabine 4 fedratinib 4 belinostat 4 Rituximab 4 Cytarabine 4 Bortezomib 4 ARQ531 4 pomalidomide 3 ibrutinib 3 daratumumab 3 cc-486 3 angiotensin I (1-7) 3 Lenalidomide 3 Imatinib Mesylate 3 Dexamethasone 3 Daunorubicin 3 Cyclophosphamide 3 tosedostat 2 tazemetostat 2 tanespimycin 2 talquetamab 2 tafasitamab 2 romidepsin 2 pembrolizumab 2 ixazomib 2 glasdegib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05205252 2023-08-15

ARIA

Ipsen

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡